# KEYNOTE-598 (NCT03302234)

> Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03302234
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Pembrolizumab; Ipilimumab; Placebo
- Enrollment: 568
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- YouTube: 3
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-598-nct03302234

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03302234", "email": "<work email>"}; the inbox owner confirms by the emailed link.